Aim immunotech completes all treatments in phase 1 human safety study of intranasal administration of ampligen

Company is planning a phase 2 study of its drug as a broad-spectrum respiratory virus prophylaxis company is planning a phase 2 study of its drug as a broad-spectrum respiratory virus prophylaxis

AIM Ratings Summary

AIM Quant Ranking